FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology and pharmacology, and can be used to select the optimal dose at which the preparation exhibits maximum antioxidant activity for introduction into the conjunctival cavity in eye diseases in an experiment. Lachrymal fluid is collected using filter paper, eluted with normal saline and centrifuged. Series of solutions of the analysed preparation is prepared by serial dilutions thereof with 0.05 M phosphate buffer solution pH 7.4 to concentrations of 0.015 to 14.54 mM. Solution of the analysed preparation is then added to the supernatant at ratio of 1:1 and the total antioxidant activity is assessed at the analysed concentrations of the preparation by a chemiluminescent method in a model system of haemoglobin – hydrogen peroxide – luminol. Optimal dose is selected at which the preparation exhibits maximum total antioxidant activity.
EFFECT: invention provides obtaining objective data on antioxidant potential of tear and test preparation with selection of optimal dose of preparation with antioxidant properties for application in the form of eye drops.
1 cl, 5 dwg, 5 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS, AND A METHOD FOR USE THEREOF | 2018 |
|
RU2694226C1 |
METHOD OF EYE TREATING BURNS | 2012 |
|
RU2495651C1 |
METHOD OF TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS | 2014 |
|
RU2577236C1 |
PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION IN TREATING INFLAMMATORY EYE DISEASES AND METHOD FOR USING IT | 2012 |
|
RU2508123C1 |
AGENT FOR REDUCING INTRAOCULAR PRESSURE AND METHOD OF USE THEREOF | 2022 |
|
RU2815996C1 |
COMPOSITION WHICH REDUCES OXIDATIVE STRESS IN EYE | 2019 |
|
RU2733928C2 |
METHOD OF EXPERIMENTAL TREATMENT OF EYE NEURODEGENERATIVE PROCESS | 2023 |
|
RU2794835C1 |
METHOD FOR DETECTING ACTIVITY OF INFLAMMATORY PROCESS IN UVEITIS-PATIENTS | 2001 |
|
RU2192009C1 |
EYE DROPS FOR TREATING DRY EYE SYNDROME | 2006 |
|
RU2302231C1 |
AGENT FOR TREATMENT OF EYE DISEASES AND METHOD OF ITS USE | 2016 |
|
RU2657780C2 |
Authors
Dates
2024-10-21—Published
2024-03-11—Filed